HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF)
Condition Identity
OFFICIAL CLINICAL NAME
Heart Failure with Reduced Ejection Fraction (HFrEF)
ICD-11 CODEBD10
CLINICAL SYNONYMS & ALIASES
HFrEFSystolic Heart FailureCongestive Heart FailureLeft Ventricular Systolic Dysfunction
Epidemiology
PREVALENCEAffects over 64 million individuals worldwide
Risk Factors
- Coronary artery disease / Previous myocardial infarction (most common cause)
- Longstanding uncontrolled hypertension
- Dilated cardiomyopathy (genetic, toxic/alcohol, viral)
- Valvular heart disease (severe aortic stenosis, mitral regurgitation)
- Diabetes mellitus and metabolic syndrome
Signs & Symptoms
CLINICAL SIGNS (OBJECTIVE FINDINGS)
- Elevated Jugular Venous Pressure (JVP)
- Bilateral bibasilar inspiratory crackles / rales
- Third heart sound (S3 gallop)
- Laterally displaced apical impulse
- Bilateral pitting peripheral ankle/pedal edema
- Hepatomegaly and ascites in biventricular failure
SYMPTOMS (PATIENT-REPORTED)
- Dyspnea on exertion, progress to orthopnea and paroxysmal nocturnal dyspnea (PND)
- Persistent fatigue and exercise intolerance
- Rapid weight gain (>2 kg in 3 days) due to fluid retention
- Nocturnal dry cough
Complications
DOWNSTREAM CLINICAL COMPLICATIONS & SEQUELAE
- Acute decompensated pulmonary edema
- Cardiogenic shock and end-organ hypoperfusion (cardiorenal syndrome)
- Ventricular arrhythmias (VT/VF) and sudden cardiac death
- Atrial fibrillation with rapid ventricular response and thromboembolism
Diagnostic Criteria
Investigations
POINT-OF-CARE
Bedside Tests
- 12-lead ECG (arrhythmias, prior Q waves, bundle branch block)
- SpO2 and daily weight
PRIMARY WORKUP
First-Line Diagnostic Tests
- Plasma Natriuretic Peptides: BNP > 35 pg/mL or NT-proBNP > 125 pg/mL in non-acute setting
- Transthoracic Echocardiogram (TTE) - Definitive for LVEF, chamber dimensions, diastolic function & valvular abnormalities
- Renal function (BUN, creatinine, eGFR), electrolytes, CBC, iron studies (ferritin & TSAT), thyroid function (TSH)
- Chest X-ray (cardiomegaly, upper lobe venous diversion, Kerley B lines, pleural effusion)
GOLD STANDARD
Confirmatory & Specialized Tests
- Cardiac MRI (myocardial tissue characterization)
- Coronary angiography (rule out ischemic etiology)
Nonpharmacological Management
- Sodium restriction (< 2-3 g/day) and fluid restriction (1.5-2 L/day for congested patients)
- Daily morning weight monitoring after voiding before breakfast
- Supervised cardiac rehabilitation exercise program for stable patients
- Smoking cessation and alcohol abstinence
Monitoring
Prevention
- Aggressive treatment of hypertension, hyperlipidemia, and diabetes
- Prompt revascularization in acute coronary syndrome
- Annual influenza and pneumococcal vaccination
Prognosis
CLINICAL COURSE & EXPECTED OUTCOMES
GDMT with the 4 foundational pillars significantly reduces all-cause mortality by >60% and halves heart failure hospitalizations.
Referral Criteria
CLINICAL NOTICE & EDUCATIONAL DISCLAIMER
All content in Medobo is for educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional and local institutional protocols before administering medication or initiating treatment.